• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The SOME trial: Screening for occult malignancy in unprovoked venous thromboembolism [Classics Series]

byAndrew Cheung, MD MBA
November 20, 2015
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with a first unprovoked venous thromboembolism were randomized to either limited-screening for occult malignancy or limited-screening plus computed tomography (CT) of the abdomen and pelvis.

2. There were no significant differences between the two strategies in the number of occult malignancies diagnosed, and the number of occult malignancies missed by the initial screen.

Original Date of Publication: August 2015

Study Rundown: Venous thromboembolism is a common class of disease characterized by the formation of clots in the deep veins. These clots can be classified as being provoked, or unprovoked in the absence of a known risk factor (i.e., overt active cancer, current pregnancy, thrombophilia, previous clot, recent immobilization, recent major surgery). Unprovoked venous thromboembolism has been thought to be an early sign of cancer, as previous studies had demonstrated that up 10% of patients were diagnosed with malignancy in the year afterwards. Thus, an area of uncertainty for clinicians was how aggressively patients with unprovoked venous thromboembolism should be investigated for occult malignancy. The Screening for Occult Malignancy in Patients with Idiopathic Venous Thromboembolism (SOME) trial sought to address this question.

In summary, the trial randomized individuals with unprovoked venous thromboembolism to either limited-screening for occult malignancy or to limited-screening plus comprehensive CT of the abdomen and pelvis. There were no significant differences between the two groups in the number of occult malignancies identified. There were also no significant differences between the two strategies in the number of malignancies initially missed on screening, but subsequently discovered. Based on these findings, a strategy of conducting limited-screening for occult malignancy may be appropriate for individuals who present with a first unprovoked venous thromboembolism.

Click to read the study in NEJM

In-Depth [randomized controlled trial]: A total of 854 patients from 9 participating Canadian centers were included in the intention-to-test analysis. Patients were eligible if they had a new diagnosis of first unprovoked symptomatic venous thromboembolism (i.e., proximal lower extremity deep-vein thrombosis, pulmonary embolism, or both). Exclusion criteria included age <18 years, refusal or inability to provide informed consent, allergy to contrast media, creatinine clearance <60 mL/minute, weight >130 kg, ulcerative colitis, and glaucoma. Included patients were randomized in a 1:1 fashion to receive either limited occult-cancer screening (i.e., basic bloodwork, chest radiography, and recommended sex-specific screening) or limited occult-cancer screening plus comprehensive CT scan of the abdomen and pelvis. The primary outcome was newly diagnosed cancer during the 1-year follow-up period in patients with negative screen for occult malignancy. Secondary outcomes were the number of occult malignancies diagnosed, the number of early cancers diagnosed in screening and during follow-up, the incidence of recurrent venous thromboembolism, 1-year cancer-related mortality, and 1-year overall mortality.

RELATED REPORTS

COVID-19 pandemic associated with reductions in delivery of cancer care services in Ontario, Canada

SARS-CoV-2 infection during pregnancy associated with severe maternal morbidity, preterm birth, and venous thromboembolism

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

There were no significant differences between the two groups in the number of occult cancers diagnosed. A total of 14 patients (3.2%; 95%CI 1.9 to 5.4%) in the limited-screening group and 19 patients (4.5%; 95%CI 2.9 to 6.9%) in the limited-screening plus CT group received diagnoses of occult cancers (p = 0.28). In both groups, several occult malignancies were missed by the initial screening strategies, with 4 (29%; 95%CI 8 to 58%) missed in the limited-screening group and 5 (26%; 95%CI 9 to 51%) missed in the limited-screening plus CT group (p = 1.0). Kaplan-Meier analysis showed that there was no significant difference in time to detection of missed occult cancers between the two groups (p = 0.87). There were no significant differences between the groups in the incidence of recurrent venous thromboembolism (p = 1.0), cancer-related mortality (p = 0.75), or overall mortality (p = 1.0).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancer screeningsome trialvenous thromboembolism
Previous Post

Sofosbuvir-velpatasvir may provide sustained virologic response in Hepatitis C cirrhotics: The ASTRAL-4 study

Next Post

The Magpie trial: Magnesium lowers eclampsia risk [Classics Series]

RelatedReports

Chronic Disease

COVID-19 pandemic associated with reductions in delivery of cancer care services in Ontario, Canada

April 29, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Hematology

SARS-CoV-2 infection during pregnancy associated with severe maternal morbidity, preterm birth, and venous thromboembolism

March 24, 2022
#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19
StudyGraphics

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

January 26, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Cardiology

Aspirin use was not effective at reducing mortality in patients hospitalized with COVID-19

January 25, 2022
Next Post
Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The Magpie trial: Magnesium lowers eclampsia risk [Classics Series]

Infertility treatments not associated with increased short-term cancer risk

Donor egg cycles more successful than autologous oocytes in cancer survivors

High incidence of cognitive impairment associated with colorectal cancer

High incidence of cognitive impairment associated with colorectal cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Treatment of anal high-grade squamous intraepithelial lesions can reduce rates of progression to invasive anal cancer.
  • High tumour mutation burden in NSCLC associated with improved clinical outcomes of PD-L1 blockade across PD-L1 expression subgroups
  • Subsidization of supermarkets may help reduce obesity risk in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.